Cognitive Impairment Associated with Schizophrenia (CIAS) – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

    1.1. Report Overview

2. Cognitive Impairment Associated with Schizophrenia (CIAS) - Overview

3. Executive Summary

4. Cognitive Impairment Associated with Schizophrenia (CIAS) : Pipeline Assessment

    4.1. By Stage of Development

    4.2. By Route of Administration

    4.3. By Drug Class

    4.4. By Molecule Type

    4.5. By Therapy Area / Indication

    4.6. By Drug Target

    4.7. By Sponsor

5. Cognitive Impairment Associated with Schizophrenia (CIAS): Company & Drug Profiles

    5.1. Clinical Stage

        5.1.1. BIIB104 – Biogen

            5.1.1.1. Company Overview

            5.1.1.2. Product Description

            5.1.1.3. R&D Status & Development Activities

            5.1.1.4. Mechanism of Action

            5.1.1.5. Molecule Type

            5.1.1.6. Stage of Development

            5.1.1.7. Indications

            5.1.1.8. Route of Administration

            5.1.1.9. Funding

        5.1.2. Basmisanil – F. Hoffmann-La Roche Ltd.

            5.1.2.1. Company Overview

            5.1.2.2. Product Description

            5.1.2.3. R&D Status & Development Activities

            5.1.2.4. Mechanism of Action

            5.1.2.5. Molecule Type

            5.1.2.6. Stage of Development

            5.1.2.7. Indications

            5.1.2.8. Route of Administration

            5.1.2.9. Funding

        5.1.3. PF-03463275 – Yale University

            5.1.3.1. Company Overview

            5.1.3.2. Product Description

            5.1.3.3. R&D Status & Development Activities

            5.1.3.4. Mechanism of Action

            5.1.3.5. Molecule Type

            5.1.3.6. Stage of Development

            5.1.3.7. Indications

            5.1.3.8. Route of Administration

            5.1.3.9. Funding

        5.1.4. Others

    5.2. Preclinical

        5.2.1. Company Overview

        5.2.2. Product Description

        5.2.3. R&D Status & Development Activities

        5.2.4. Mechanism of Action

        5.2.5. Molecule Type

        5.2.6. Indications

        5.2.7. Route of Administration

        5.2.8. Funding

6. Cognitive Impairment Associated with Schizophrenia (CIAS): An Overview on Dormant & Discontinued Pipeline Candidates

    6.1. Overview

    6.2. Product Description

    6.3. Reason for Discontinuation

7. Cognitive Impairment Associated with Schizophrenia (CIAS): Additional Key Insights

    7.1. Epidemiology Overview: Cognitive Impairment Associated with Schizophrenia (CIAS)

    7.2. Current Market Scenario: Cognitive Impairment Associated with Schizophrenia (CIAS) Therapeutics

8. Cognitive Impairment Associated with Schizophrenia (CIAS): News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.